Journal Article10.1111/bph.70085
Dexrazoxane protects against doxorubicin-induced cardiotoxicity in susceptible human living myocardial slices: A proof-of-concept study.
J. S. A. van der Geest,I. R. Kelters,Bauke K. O. Arends,Willem B. van Ham,E. D. Benavente,Thirza A Lapré,Petra van der Kraak,P. Van der Harst,Arco J. Teske,Andreas Dendorfer,M. M. Mokhles,Pieter A Doevendans,T. P. de Boer,Linda W. van Laake,J. P. Sluijter,V. Sampaio-Pinto +15 more
1
TL;DR: This proof-of-concept study investigates dexrazoxane's cardioprotective effects against doxorubicin-induced cardiotoxicity in human living myocardial slices, providing a novel model for exploring cardiotoxicity and potential treatments in cancer survivors.
read more
Abstract: The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Quercetin ameliorates doxorubicin-induced atrial fibrillation via EGFR-mediated restoration of autophagic flux
Wei Hua Bian,Shi Hao Wang,Ze-Chun Kang,Yong Xu,Ya-Nuo Li,Mei Zi Yang,Jun-yao LIU,YAN Li-Cheng,Dong Chang,Xin Xie +9 more
References
•Proceedings Article
beta-VAE: Learning Basic Visual Concepts with a Constrained Variational Framework
Irina Higgins,Loic Matthey,Arka Pal,Christopher P. Burgess,Xavier Glorot,Matthew Botvinick,Shakir Mohamed,Alexander Lerchner +7 more
- 24 Apr 2017
TL;DR: In this article, a modification of the variational autoencoder (VAE) framework is proposed to learn interpretable factorised latent representations from raw image data in a completely unsupervised manner.
5K
Doxil®--the first FDA-approved nano-drug: lessons learned.
TL;DR: This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use and demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles.
3.9K
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
TL;DR: Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug, which is reflected in the incidence in the broader clinical oncology setting.
2.1K
Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Paul W. Burridge,Yong Fuga Li,Elena Matsa,Haodi Wu,Sang-Ging Ong,Arun Sharma,Alexandra Holmström,Alex C.Y. Chang,Michael Coronado,Antje D. Ebert,Joshua W. Knowles,Melinda L. Telli,Ronald M. Witteles,Helen M. Blau,Daniel Bernstein,Russ B. Altman,Joseph C. Wu +16 more
TL;DR: It is demonstrated that patient-specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) can recapitulate the predilection to doxorubicin-induced cardiotoxicity of individual patients at the cellular level.
NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
Leszek Wojnowski,Bettina Kulle,Markus D. Schirmer,Gregor Schlüter,Albrecht Schmidt,Albert Rosenberger,Stefan Vonhof,Heike Bickeböller,Mohammad R. Toliat,Eun-Kyung Suk,Mladen V. Tzvetkov,Anke Kruger,Silvia Seifert,Marita Kloess,Heidi Hahn,Markus Loeffler,Peter Nürnberg,Michael Pfreundschuh,Lorenz Trümper,Jürgen Brockmöller,Gerd Hasenfuss +20 more
TL;DR: Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT.
496